



IVI Releases Public Comments on Non-Small Cell Lung Cancer Value Tool

Alexandria, VA – July 18, 2019 -- The non-profit [Innovation and Value Initiative](#) (IVI) today released public comments on the Open-Source Value Project (OSVP) model to assess value among treatment sequences for epidermal growth factor receptor positive (EGFR+), non-squamous non-small cell lung cancer (NSCLC).

“IVI is committed to transparency, collaboration and iterating value models that provide end-users with needed flexibility to understand value – especially in the rapidly evolving therapeutic landscape of diseases like non-small cell lung cancer,” said Jennifer Bright, IVI’s executive director. “We appreciate the constructive feedback contained in the comments and the clear commitment to moving value assessment forward on the part of those who submitted them.”

A number of the comments addressed the need for additional and customized inputs to support both Cost Effectiveness Analysis (CEA) and Multi-Criteria Decision Analysis (MCDA).

“One key takeaway from the totality of the comments is end-users’ need for multiple approaches to assess the value of sequential therapies in highly heterogeneous patient populations,” said Mark Linthicum, IVI’s director of scientific communications. “Capturing the many dimensions that determine value – whether in terms of clinical outcomes or broader impacts on patients or society – is both challenging and essential. The comments indicate that the multi-faceted value assessment approaches offered by IVI’s models produce a richer overall value picture for end users than more static approaches. We look forward to building on the model to enhance its utility for all end users.”

IVI models are developed iteratively with feedback and suggestions from interested healthcare stakeholders. After the initial release of the model in non-small cell lung cancer (IVI-NSCLC), IVI initiated an eight-week open comment period, which ended April 1.

All of the public comments submitted to IVI are now posted on [IVI’s website](#). The comments will be reviewed by a [Technical Expert Panel \(TEP\)](#) engaged by IVI to synthesize feedback and recommend prioritized modifications. The TEP will issue a final report with prioritized recommendations for model improvements later in 2019. The report will guide subsequent model updates.

The IVI-NSCLC is the second value assessment model developed by IVI. The first, which assesses therapy sequences in rheumatoid arthritis, followed the same public comment and TEP review process prior will release a partial model update this summer.

Media Contact: Eric Hoffman | ehoffman@schmidtpa.com

About IVI

The Innovation and Value Initiative IVI is a nonprofit organization committed to advancing the science and improving the practice of value assessment in healthcare through collaboration among thought leaders in academia, patient organizations, payers, life science firms, providers, delivery systems and other organizations.